Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis (VIDEO)
Caption
A UCalgary study has found promising results for the generic drug hydroxychloroquine when used to reduce the worsening of disability of primary progressive multiple sclerosis (MS), the least treatable form of the autoimmune disease. MS affects about 90,000 Canadians, one of the highest rates in the world with about 15 per cent of those diagnosed with primary progressive MS.
Credit
Hotchkiss Brain Institute
Usage Restrictions
None.
License
Original content